Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Astero Erado Inc
Profile last edited on: 7/19/2022      CAGE: 8HE35      UEI: Z3JWEMNYNRT9

Business Identifier: Advanced therapeutics through antibody-engineering
Year Founded
2020
First Award
2021
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

8405 Spring Creek
College Station, TX 77845
   (214) 219-4198
   admin@asteroerado.com
   www.asteroerado.com
Location: Single
Congr. District: 10
County: Brazos

Public Profile

Currently resident in Houston (JLABS @ TMC) , Astero Erado Inc is structured around first in class technology for the removal of pathogenic auto antibodies through selective antigen depletion. Principals of the fiirm indicate that they are developing the Seldeg approach to remove these auto antibodies. - ith the firm's product stage indicated as Preclinical (GLP Tox-IND)

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$749,108
Phase II Dollars
$0
Total Awarded
$749,108

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $1,267,956
Project Title: Depleting autoantibodies for the treatment of autoimmunity
2021 1 NIH $250,915
Project Title: Targeting autoreactive antibodies for the therapy of MOG antibody-associated disease
2021 1 NIH $246,229
Project Title: Autoantibody depletion for the therapy of autoimmune disease
0 1 NIH $305,360
Project Title: Novel treatments for Autoimmune Disease
0 1 NIH $275,213
Project Title: Novel approaches for the treatment of autoimmune disease

Key People / Management

  Raimund Ober -- CEO

  Sushrut Arora -- Principle Scientist

  Sunil Kannanganat Sidharthan -- Principal Scientist

Company News

There are no news available.